JP2019503337A5 - - Google Patents

Download PDF

Info

Publication number
JP2019503337A5
JP2019503337A5 JP2018522784A JP2018522784A JP2019503337A5 JP 2019503337 A5 JP2019503337 A5 JP 2019503337A5 JP 2018522784 A JP2018522784 A JP 2018522784A JP 2018522784 A JP2018522784 A JP 2018522784A JP 2019503337 A5 JP2019503337 A5 JP 2019503337A5
Authority
JP
Japan
Prior art keywords
methyl
compound
pharmaceutically acceptable
difluoromethyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018522784A
Other languages
English (en)
Japanese (ja)
Other versions
JP6877423B2 (ja
JP2019503337A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/076932 external-priority patent/WO2017080979A1/en
Publication of JP2019503337A publication Critical patent/JP2019503337A/ja
Publication of JP2019503337A5 publication Critical patent/JP2019503337A5/ja
Application granted granted Critical
Publication of JP6877423B2 publication Critical patent/JP6877423B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018522784A 2015-11-09 2016-11-08 がんの処置において有用なジヒドロイミダゾピラジノン誘導体 Active JP6877423B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562252726P 2015-11-09 2015-11-09
US62/252,726 2015-11-09
US201662401351P 2016-09-29 2016-09-29
US62/401,351 2016-09-29
PCT/EP2016/076932 WO2017080979A1 (en) 2015-11-09 2016-11-08 Dihydroimidazopyrazinone derivatives useful in the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2019503337A JP2019503337A (ja) 2019-02-07
JP2019503337A5 true JP2019503337A5 (https=) 2020-04-16
JP6877423B2 JP6877423B2 (ja) 2021-05-26

Family

ID=57241113

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018522784A Active JP6877423B2 (ja) 2015-11-09 2016-11-08 がんの処置において有用なジヒドロイミダゾピラジノン誘導体

Country Status (35)

Country Link
US (2) US9902731B2 (https=)
EP (1) EP3374359B1 (https=)
JP (1) JP6877423B2 (https=)
KR (1) KR20180074788A (https=)
CN (1) CN108349983B (https=)
AU (1) AU2016351813B2 (https=)
BR (1) BR112018008397B1 (https=)
CA (1) CA3003549A1 (https=)
CL (1) CL2018001226A1 (https=)
CO (1) CO2018004857A2 (https=)
CR (1) CR20180316A (https=)
CY (1) CY1123627T1 (https=)
DK (1) DK3374359T3 (https=)
EA (1) EA038028B1 (https=)
ES (1) ES2780650T3 (https=)
HR (1) HRP20200342T1 (https=)
IL (1) IL258953A (https=)
LT (1) LT3374359T (https=)
ME (1) ME03770B (https=)
MX (1) MX376639B (https=)
MY (1) MY197626A (https=)
NI (1) NI201800058A (https=)
PE (1) PE20181288A1 (https=)
PH (1) PH12018500987A1 (https=)
PL (1) PL3374359T3 (https=)
PT (1) PT3374359T (https=)
RS (1) RS60155B1 (https=)
SG (1) SG11201803066VA (https=)
SI (1) SI3374359T1 (https=)
SM (1) SMT202000152T1 (https=)
SV (1) SV2018005687A (https=)
TN (1) TN2018000119A1 (https=)
TW (1) TWI730012B (https=)
WO (1) WO2017080979A1 (https=)
ZA (1) ZA201803742B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3365334B1 (en) 2015-10-21 2024-07-17 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
RS60155B1 (sr) * 2015-11-09 2020-05-29 Astrazeneca Ab Derivati dihidroimidazopirazinona korisni za upotrebu u tretmanu raka
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
US20210386737A1 (en) * 2018-10-10 2021-12-16 Shenzhen Targetrx, Inc. Dihydroimidazopyrazinone compound, composition including same, and use thereof
BR112021017957A2 (pt) 2019-03-28 2021-11-23 Jiangsu Hengrui Medicine Co Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo
JP2022534224A (ja) 2019-05-24 2022-07-28 江蘇恒瑞医薬股▲ふん▼有限公司 置換縮合二環式誘導体、その調製方法、および医薬におけるその適用
MX2021014961A (es) 2019-06-06 2022-01-24 Hutchison Medipharma Ltd Compuestos triciclicos y su uso.
AU2020397222B2 (en) * 2019-12-05 2023-07-06 Astrazeneca Ab Process and intermediates for the production of formula (i)
WO2021110169A1 (zh) * 2019-12-06 2021-06-10 南京明德新药研发有限公司 作为erk抑制剂的噻唑并内酰胺类化合物及其应用
WO2022068860A1 (zh) 2020-09-29 2022-04-07 江苏恒瑞医药股份有限公司 一种吡咯并杂环类衍生物的晶型及其制备方法
CN117529321A (zh) * 2021-06-18 2024-02-06 上海德琪医药科技有限公司 Erk抑制剂和kras抑制剂的组合及其用途
WO2022268065A1 (en) * 2021-06-22 2022-12-29 Fochon Biosciences, Ltd. Compounds as erk inhibitors
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
US20250127789A1 (en) 2021-11-04 2025-04-24 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
US20250340570A1 (en) 2022-04-27 2025-11-06 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
US20250304593A1 (en) 2022-05-12 2025-10-02 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2024006971A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US7485640B2 (en) * 2002-11-06 2009-02-03 Merck Sharp & Dohme Limited Imidazopyrazinones as GABA-A receptor anxiolytics
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
CN101611007A (zh) * 2006-12-20 2009-12-23 先灵公司 新颖的jnk抑制剂
SG191097A1 (en) * 2010-12-22 2013-08-30 Janssen Pharmaceutica Nv 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
SG11201502728WA (en) * 2011-10-10 2015-05-28 Lundbeck & Co As H Pde9i with imidazo pyrazinone backbone
JP2013166727A (ja) * 2012-02-16 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ジヒドロイミダゾピラジノン誘導体
HUE053994T2 (hu) 2012-03-01 2021-08-30 Array Biopharma Inc Szerin/treonin kináz inhibitorok
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
EP3077401B1 (en) * 2013-12-06 2018-04-18 Genentech, Inc. Serine/threonine kinase inhibitors
KR102379517B1 (ko) 2013-12-30 2022-03-25 제넨테크, 인크. 세린/트레오닌 키나아제 억제제
JP6642942B2 (ja) * 2013-12-30 2020-02-12 アレイ バイオファーマ、インコーポレイテッド セリン/トレオニンキナーゼ阻害剤
MY188526A (en) 2014-04-09 2021-12-18 Genentech Inc Process for the manufacturing of medicaments
US10412619B2 (en) * 2014-11-14 2019-09-10 Qualcomm Incorporated Buffer status report for eDCS
WO2016162325A1 (en) * 2015-04-07 2016-10-13 Astrazeneca Ab Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors
WO2016192064A1 (en) 2015-06-03 2016-12-08 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds for treating psoriasis
CN107849046B (zh) 2015-06-03 2020-06-12 常州捷凯医药科技有限公司 作为erk抑制剂的杂环化合物
RS60155B1 (sr) * 2015-11-09 2020-05-29 Astrazeneca Ab Derivati dihidroimidazopirazinona korisni za upotrebu u tretmanu raka

Similar Documents

Publication Publication Date Title
JP2019503337A5 (https=)
HRP20200342T1 (hr) Derivati dihidroimidazopirazinona korisni u liječenju raka
JP2017535561A5 (https=)
JP2018533611A5 (https=)
JP2016529292A5 (https=)
JP2016522232A5 (https=)
JP2019534260A5 (https=)
JP2016537384A5 (https=)
RU2017140446A (ru) Гетероарильное производное или его фармацевтически приемлемая соль, способ их получения и фармацевтическая композиция для профилактики или лечения заболеваний, связанных с pi3 киназами, содержащая данное действующее вещество
RU2017121278A (ru) Триазоло-пиразинильные производные, применимые в качестве растворимых активаторов гуанилатциклазы
JP2016520116A5 (https=)
JP2017527548A5 (https=)
JP2011507854A5 (https=)
RU2016140338A (ru) Азаспиро производные в качестве антагонистов trpm8
JP2016525075A5 (https=)
EP3004060A1 (en) Compounds for kinase modulation, and indications therefor
JP2022500402A5 (https=)
JP2016514719A5 (https=)
JP2014513110A5 (https=)
SI2935248T1 (en) Compounds and procedures for kinase modulation and indications for the latter
JP2016525076A5 (https=)
JP2015504061A5 (https=)
JP2018529731A5 (https=)
NZ600229A (en) Triazolopyridines
JP2007528379A5 (https=)